glycerophosphocholine - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	glycerophosphocholine	go back to main search page
Accession:	CHEBI:36313	browse the term
Definition:	The glycerol phosphate ester of a phosphocholine. A nutrient with many different roles in human health.
Synonyms:	related_synonym:	glycerophosphocholines
	alt_id:	CHEBI:26698; CHEBI:35763
	xref:	PMID:8467564

show annotations for term's descendants Sort by:
Rat (124) Mouse (126) Human (127) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (124)

1,2-dihexadecanoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 6

multiple interactions

1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

prion protein

multiple interactions
affects folding

Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form]

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-O-oleoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

SMAD family member 3

decreases abundance

SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

arachidonate 5-lipoxygenase

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine receptor 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

Cd68 molecule

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

C-reactive protein

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

gap junction protein, alpha 1

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

interleukin 1 alpha

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium voltage-gated channel subfamily A regulatory beta subunit 2

multiple interactions

[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine

NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

oxidized low density lipoprotein receptor 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

platelet-activating factor receptor

affects binding
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin E

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

TIMP metallopeptidase inhibitor 4

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

tumor necrosis factor

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

increases hydrolysis

LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

1-stearoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

2-acetyl-1-alkyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

Platelet Activating Factor results in increased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

arachidonate 12-lipoxygenase, 12S type

increases expression

Platelet Activating Factor results in increased expression of ALOX12 mRNA

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 5-lipoxygenase

multiple interactions
increases expression

[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor]
Platelet Activating Factor results in increased expression of ALOX5 mRNA

PMID:8387780 PMID:10779545 PMID:16386258

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine ligand 2

multiple interactions
increases secretion

Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine receptor 2

increases expression

Platelet Activating Factor results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-reactive protein

increases expression

Platelet Activating Factor results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

C-X3-C motif chemokine receptor 1

increases expression

Platelet Activating Factor results in increased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

endothelin 1

multiple interactions
increases abundance

Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type B

multiple interactions

EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

early growth response 1

increases expression

Platelet Activating Factor results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

glucuronidase, beta

multiple interactions

[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

interleukin 1 alpha

increases expression

Platelet Activating Factor results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression
increases secretion
multiple interactions

Platelet Activating Factor results in increased expression of IL1B mRNA
Platelet Activating Factor results in increased secretion of IL1B protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]

PMID:16386258 PMID:32830409

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases secretion

[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]

PMID:9762784 PMID:11116075

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

leukotriene B4 receptor

affects response to substance

LTB4R1 protein affects the susceptibility to Platelet Activating Factor

NCBI chr15:29,263,199...29,265,716

G

matrix metallopeptidase 13

increases expression

Platelet Activating Factor results in increased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

MYD88, innate immune signal transduction adaptor

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of MYD88 protein
PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

neutral cholesterol ester hydrolase 1

multiple interactions

NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588

G

NFKB inhibitor alpha

multiple interactions
increases degradation

Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

oxidized low density lipoprotein receptor 1

increases expression

Platelet Activating Factor results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

phospholipase A2 group VII

multiple interactions
increases expression

[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA]

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

peroxisome proliferator activated receptor alpha

decreases expression

Platelet Activating Factor results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

platelet-activating factor receptor

multiple interactions
increases expression
increases phosphorylation
affects binding

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
Platelet Activating Factor results in increased expression of PTAFR mRNA
Platelet Activating Factor results in increased phosphorylation of PTAFR protein
bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]

PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 More...

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases expression

Platelet Activating Factor results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases expression

Platelet Activating Factor results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

Pvt1 oncogene

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of PVT1 mRNA
[Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]

NCBI chr 7:93,656,528...93,879,938

G

regulator of G-protein signaling 4

multiple interactions

RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

selectin E

increases expression

Platelet Activating Factor results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selectin L

multiple interactions
increases secretion

Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

selectin P

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein]

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

TIMP metallopeptidase inhibitor 4

increases expression

Platelet Activating Factor results in increased expression of TIMP4 mRNA

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

Platelet Activating Factor results in increased secretion of TNF protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
Platelet Activating Factor results in increased expression of TNF mRNA
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]

PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma

RGD

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

edelfosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

multiple interactions

edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein]

PMID:9295281 PMID:12421819

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

F2R like trypsin receptor 1

multiple interactions

edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]]

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

leptin

multiple interactions

edelfosine inhibits the reaction [LEP protein results in increased transport of Calcium]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

phospholipase C, beta 2

multiple interactions

edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PLCB2 protein]

NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302

G

prostaglandin-endoperoxide synthase 2

increases expression

edelfosine results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

transient receptor potential cation channel, subfamily A, member 1

multiple interactions

edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]]

NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570

glycerylphosphorylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glycerophosphodiester phosphodiesterase domain containing 5

affects abundance

GDPD5 protein affects the abundance of Glycerylphosphorylcholine

NCBI chr 1:153,679,718...153,761,452
Ensembl chr 1:153,679,718...153,761,446

G

patatin-like phospholipase domain containing 6

affects abundance

PNPLA6 protein affects the abundance of Glycerylphosphorylcholine

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734

lysophosphatidylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

basic helix-loop-helix ARNT like 1

affects abundance

BMAL1 gene mutant form affects the abundance of Lysophosphatidylcholines

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

caspase 3

increases expression
multiple interactions

Lysophosphatidylcholines results in increased expression of CASP3 protein
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caveolin 1

multiple interactions
increases expression

alpha-Tocopherol inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 protein]
Lysophosphatidylcholines results in increased expression of CAV1 mRNA; Lysophosphatidylcholines results in increased expression of CAV1 protein

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions

[[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

ectonucleotide pyrophosphatase/phosphodiesterase 7

increases hydrolysis

ENPP7 protein results in increased hydrolysis of Lysophosphatidylcholines

NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589

G

fascin actin-bundling protein 1

increases expression

Lysophosphatidylcholines results in increased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

gap junction protein, alpha 1

increases ubiquitination
multiple interactions

Lysophosphatidylcholines results in increased ubiquitination of GJA1 protein
Lysophosphatidylcholines affects the localization of and results in increased phosphorylation of GJA1 protein; PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

G protein-coupled receptor 4

increases expression
multiple interactions

Lysophosphatidylcholines results in increased expression of GPR4 mRNA; Lysophosphatidylcholines results in increased expression of GPR4 protein
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein]

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

heme oxygenase 1

increases expression

Lysophosphatidylcholines results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

increases expression
multiple interactions

Lysophosphatidylcholines results in increased expression of ICAM1 mRNA
quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 18

increases expression
multiple interactions

Lysophosphatidylcholines results in increased expression of IL18 protein
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

increases expression
multiple interactions

Lysophosphatidylcholines results in increased expression of IL1B protein
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 33

increases expression
multiple interactions

Lysophosphatidylcholines results in increased expression of IL33 protein
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

laminin subunit alpha 3

increases expression

Lysophosphatidylcholines results in increased expression of LAMA3 mRNA

NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353

G

laminin subunit beta 3

increases expression

Lysophosphatidylcholines results in increased expression of LAMB3 mRNA

NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405

G

laminin subunit gamma 2

increases expression

Lysophosphatidylcholines results in increased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MFSD2 lysolipid transporter A, lysophospholipid

increases transport

MFSD2A results in increased transport of Lysophosphatidylcholines

NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690

G

NLR family, pyrin domain containing 3

multiple interactions
increases expression

GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
decreases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Lysophosphatidylcholines

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

phenylalanine hydroxylase

multiple interactions

Lysophosphatidylcholines results in increased activity of [PAH protein binds to PAH protein binds to PAH protein binds to PAH protein]

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

patatin-like phospholipase domain containing 6

affects abundance

PNPLA6 protein affects the abundance of Lysophosphatidylcholines

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734

G

protein kinase C, epsilon

multiple interactions

PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein]

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

prostaglandin-endoperoxide synthase 1

decreases expression
multiple interactions

Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

tumor protein p53

multiple interactions

[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Lysophosphatidylcholines

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

transient receptor potential cation channel, subfamily C, member 5

multiple interactions

Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol inhibits the reaction [Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]]

NCBI chr X:107,946,163...108,230,991
Ensembl chr X:107,939,131...108,230,991

G

vascular cell adhesion molecule 1

increases expression

Lysophosphatidylcholines results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

phosphatidylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases secretion

ABCB11 protein results in increased secretion of Phosphatidylcholines

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects export
affects transport

ABCB1 protein affects the export of Phosphatidylcholines
ABCB1 protein affects the transport of Phosphatidylcholines

PMID:11147995 PMID:11745043

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

affects transport
affects export

ABCB4 protein affects the transport of Phosphatidylcholines
ABCB4 protein affects the export of Phosphatidylcholines

PMID:11745043 PMID:15696852

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

acetyl-CoA acetyltransferase 1

decreases activity

Phosphatidylcholines results in decreased activity of ACAT1 protein

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

adiponectin, C1Q and collagen domain containing

decreases expression

Phosphatidylcholines results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

aryl hydrocarbon receptor

multiple interactions
increases abundance

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

amyloid beta precursor protein

multiple interactions

[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arsenite methyltransferase

affects metabolic processing

AS3MT gene mutant form affects the metabolism of Phosphatidylcholines

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

BCL2 associated X, apoptosis regulator

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

caspase 3

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

increases expression

Phosphatidylcholines results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions

Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin dependent kinase 2

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

carboxylesterase 1D

decreases expression

Phosphatidylcholines results in decreased expression of CES1D mRNA

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

collagen type I alpha 1 chain

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

C-reactive protein

affects binding
decreases activity

CRP protein binds to Phosphatidylcholines
Phosphatidylcholines results in decreased activity of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects activity

Phosphatidylcholines affects the activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450 family 7 subfamily A member 1

increases activity

Phosphatidylcholines results in increased activity of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

ectonucleotide pyrophosphatase/phosphodiesterase 7

increases hydrolysis

ENPP7 protein results in increased hydrolysis of Phosphatidylcholines

NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589

G

fatty acid synthase

multiple interactions

[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

decreases abundance

FGF19 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glutathione peroxidase 4

multiple interactions

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases activity

Phosphatidylcholines results in increased activity of HMGCR protein

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

insulin-like growth factor 1

increases degradation

IGF1 protein results in increased degradation of Phosphatidylcholines

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 10

increases expression

Phosphatidylcholines results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
multiple interactions

Phosphatidylcholines results in increased expression of IL1B mRNA
Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein

PMID:23911798 PMID:30958839

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression

Phosphatidylcholines results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin

decreases expression

Phosphatidylcholines results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase C, hepatic type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPC gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipase E, hormone sensitive type

increases expression

Phosphatidylcholines results in increased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lipase G, endothelial type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPG gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lactotransferrin

multiple interactions

[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

matrix metallopeptidase 2

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

NADPH oxidase 4

multiple interactions

NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

nuclear receptor subfamily 0, group B, member 2

decreases abundance

NR0B2 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

platelet-activating factor acetylhydrolase 1b, regulatory subunit 1

multiple interactions
increases secretion

PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines]
PAFAH1B1 protein results in increased secretion of Phosphatidylcholines

NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808

G

platelet-activating factor acetylhydrolase 2

multiple interactions

PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 5:146,607,050...146,636,203
Ensembl chr 5:146,613,498...146,634,943

G

phosphate cytidylyltransferase 1A, choline

multiple interactions

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357

G

phosphatidylethanolamine N-methyltransferase

multiple interactions

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

perilipin 1

increases expression

Phosphatidylcholines results in increased expression of PLIN1 mRNA

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

phospholipid phosphatase 6

multiple interactions
increases chemical synthesis

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr 1:226,679,100...226,681,952
Ensembl chr 1:226,679,100...226,681,949

G

patatin-like phospholipase domain containing 2

decreases expression

Phosphatidylcholines results in decreased expression of PNPLA2 mRNA

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

patatin-like phospholipase domain containing 6

affects abundance

PNPLA6 protein affects the abundance of Phosphatidylcholines

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734

G

paraoxonase 2

increases activity
increases expression

Phosphatidylcholines results in increased activity of PON2 protein
Phosphatidylcholines results in increased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

paraoxonase 3

multiple interactions

Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855

G

peroxisome proliferator-activated receptor gamma

increases expression

Phosphatidylcholines results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 beta

increases abundance

PPARGC1B results in increased abundance of Phosphatidylcholines

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

phosphatase and tensin homolog

affects binding
multiple interactions

PTEN protein binds to Phosphatidylcholines
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

resistin

decreases expression

Phosphatidylcholines results in decreased expression of RETN mRNA

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

surfactant protein A1

multiple interactions

[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]

NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685

G

transforming growth factor, beta 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
increases expression
increases abundance

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
Phosphatidylcholines results in increased expression of TNF mRNA
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein

PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin 1

multiple interactions

[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19867
role	19837
biological role	19835
osmolyte	3456
glycerol	3186
glycerolipid	1794
glycerophospholipid	218
glycerophosphocholine	124
(3-hexadecoxy-2-hydroxy-2-methylpropyl) 2-(trimethylazaniumyl)ethyl phosphate	0
1,2-diacyl-sn-glycero-3-phosphocholine +	23
1,2-dialkyl-sn-glycero-3-phosphocholine +	0
1-(alk-1-enyl)-2-acyl-glycero-3-phosphocholine +	0
1-(alk-1-enyl)glycero-3-phosphocholine +	0
1-o-hexadecyl-2-o-ethyl-sn-glycero-3-phosphocholine	0
1-octadecyl-2-(1E-ethenyl)-sn-glycero-3-phosphocholine	0
1-octadecyl-2-methylglycero-3-phosphocholine +	6
1-tetradecanyl-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholine	0
1-thio-sn-glycero-3-phosphocholine +	0
2-O-ethyl PAF C-16	0
2-methyl-3-tetradecyl-sn-glycero-1-phosphocholine	0
Glycero-3-phosphocholine	0
PC(14:0/P-18:0)	0
PC(14:0/P-18:1(11Z))	0
PC(14:0/P-18:1(9Z))	0
PC(14:1(9Z)/P-18:0)	0
PC(16:0/P-16:0)	0
PC(16:0/P-18:1(11Z))	0
PC(16:0/P-18:1(9Z))	0
PC(16:1(9Z)/P-16:0)	0
PC(16:1(9Z)/P-18:0)	0
PC(16:1(9Z)/P-18:1(11Z))	0
PC(16:1(9Z)/P-18:1(9Z))	0
PC(18:0/P-18:1(11Z))	0
PC(18:0/P-18:1(9Z))	0
PC(18:1(11Z)/P-16:0)	0
PC(18:1(11Z)/P-18:0)	0
PC(18:1(11Z)/P-18:1(11Z))	0
PC(18:1(11Z)/P-18:1(9Z))	0
PC(18:1(9Z)/P-16:0)	0
PC(18:1(9Z)/P-18:0)	0
PC(18:1(9Z)/P-18:1(11Z))	0
PC(18:1(9Z)/P-18:1(9Z))	0
PC(18:2(9Z,12Z)/P-16:0)	0
PC(18:2(9Z,12Z)/P-18:0)	0
PC(18:2(9Z,12Z)/P-18:1(11Z))	0
PC(18:2(9Z,12Z)/P-18:1(9Z))	0
PC(18:3(6Z,9Z,12Z)/P-16:0)	0
PC(18:3(6Z,9Z,12Z)/P-18:0)	0
PC(18:3(6Z,9Z,12Z)/P-18:1(11Z))	0
PC(18:3(6Z,9Z,12Z)/P-18:1(9Z))	0
PC(18:3(9Z,12Z,15Z)/P-16:0)	0
PC(18:3(9Z,12Z,15Z)/P-18:0)	0
PC(18:3(9Z,12Z,15Z)/P-18:1(11Z))	0
PC(18:3(9Z,12Z,15Z)/P-18:1(9Z))	0
PC(18:4(6Z,9Z,12Z,15Z)/P-16:0)	0
PC(18:4(6Z,9Z,12Z,15Z)/P-18:1(11Z))	0
PC(18:4(6Z,9Z,12Z,15Z)/P-18:1(9Z))	0
PC(18:4(6Z,9Z,12Z,15Z)/dm18:0)	0
PC(20:1(11Z)/P-16:0)	0
PC(20:2(11Z,14Z)/P-16:0)	0
PC(20:2(11Z,14Z)/P-18:1(11Z))	0
PC(20:2(11Z,14Z)/P-18:1(9Z))	0
PC(20:3(5Z,8Z,11Z)/P-16:0)	0
PC(20:3(5Z,8Z,11Z)/P-18:0)	0
PC(20:3(5Z,8Z,11Z)/P-18:1(11Z))	0
PC(20:3(5Z,8Z,11Z)/P-18:1(9Z))	0
PC(20:3(8Z,11Z,14Z)/P-16:0)	0
PC(20:3(8Z,11Z,14Z)/P-18:0)	0
PC(20:3(8Z,11Z,14Z)/P-18:1(11Z))	0
PC(20:3(8Z,11Z,14Z)/P-18:1(9Z))	0
PC(20:4(5Z,8Z,11Z,14Z)/P-16:0)	0
PC(20:4(5Z,8Z,11Z,14Z)/P-18:0)	0
PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z))	0
PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z))	0
PC(20:4(8Z,11Z,14Z,17Z)/P-16:0)	0
PC(20:4(8Z,11Z,14Z,17Z)/P-18:0)	0
PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z))	0
PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z))	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-16:0)	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0)	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z))	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z))	0
PC(22:2(13Z,16Z)/P-18:1(11Z))	0
PC(22:2(13Z,16Z)/P-18:1(9Z))	0
PC(22:4(7Z,10Z,13Z,16Z)/P-16:0)	0
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0)	0
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0)	0
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0)	0
PC(24:0/P-18:1(11Z))	0
PC(24:0/P-18:1(9Z))	0
PC(24:1(15Z)/P-18:0)	0
PC(24:1(15Z)/P-18:1(11Z))	0
PC(24:1(15Z)/P-18:1(9Z))	0
PC(O-10:0/O-10:0)	0
PC(O-10:0/O-12:0)	0
PC(O-12:0/O-1:0)	0
PC(O-14:0/O-1:0)	0
PC(O-16:0/O-1:0)	0
PC(O-16:1(1E)/0:0)	0
PC(O-18:1(1E)/0:0)	0
PC(O-18:1(9Z)/O-1:0)	0
PC(O-1:0/2:0)	0
PC(O-1:0/O-18:0)	0
PC(O-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))	0
PC(O-24:0/18:3(9Z,12Z,15Z))	0
PC(P-14:0/0:0)	0
PC(P-16:0/18:1(11Z))	0
PC(P-16:0/18:3(6Z,9Z,12Z))	0
PC(P-16:0/18:3(9Z,12Z,15Z))	0
PC(P-16:0/18:4(6Z,9Z,12Z,15Z))	0
PC(P-16:0/20:1(11Z))	0
PC(P-16:0/20:2(11Z,14Z))	0
PC(P-16:0/20:3(5Z,8Z,11Z))	0
PC(P-16:0/20:3(8Z,11Z,14Z))	0
PC(P-16:0/20:4(8Z,11Z,14Z,17Z))	0
PC(P-16:0/22:4(7Z,10Z,13Z,16Z))	0
PC(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z))	0
PC(P-16:0/P-16:0)	0
PC(P-16:0/P-18:1(11Z))	0
PC(P-16:0/P-18:1(9Z))	0
PC(P-18:0/14:0)	0
PC(P-18:0/14:1(9Z))	0
PC(P-18:0/16:1(9Z))	0
PC(P-18:0/18:1(11Z))	0
PC(P-18:0/18:3(6Z,9Z,12Z))	0
PC(P-18:0/18:3(9Z,12Z,15Z))	0
PC(P-18:0/18:4(6Z,9Z,12Z,15Z))	0
PC(P-18:0/20:3(5Z,8Z,11Z))	0
PC(P-18:0/20:3(8Z,11Z,14Z))	0
PC(P-18:0/20:4(8Z,11Z,14Z,17Z))	0
PC(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z))	0
PC(P-18:0/24:1(15Z))	0
PC(P-18:1(11Z)/14:0)	0
PC(P-18:1(11Z)/16:0)	0
PC(P-18:1(11Z)/16:1(9Z))	0
PC(P-18:1(11Z)/18:0)	0
PC(P-18:1(11Z)/18:1(11Z))	0
PC(P-18:1(11Z)/18:1(9Z))	0
PC(P-18:1(11Z)/18:2(9Z,12Z))	0
PC(P-18:1(11Z)/18:3(6Z,9Z,12Z))	0
PC(P-18:1(11Z)/18:3(9Z,12Z,15Z))	0
PC(P-18:1(11Z)/18:4(6Z,9Z,12Z,15Z))	0
PC(P-18:1(11Z)/20:2(11Z,14Z))	0
PC(P-18:1(11Z)/20:3(5Z,8Z,11Z))	0
PC(P-18:1(11Z)/20:3(8Z,11Z,14Z))	0
PC(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z))	0
PC(P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))	0
PC(P-18:1(11Z)/22:2(13Z,16Z))	0
PC(P-18:1(11Z)/24:0)	0
PC(P-18:1(11Z)/24:1(15Z))	0
PC(P-18:1(11Z)/P-16:0)	0
PC(P-18:1(11Z)/P-18:1(11Z))	0
PC(P-18:1(11Z)/P-18:1(9Z))	0
PC(P-18:1(9Z)/14:0)	0
PC(P-18:1(9Z)/16:0)	0
PC(P-18:1(9Z)/16:1(9Z))	0
PC(P-18:1(9Z)/18:0)	0
PC(P-18:1(9Z)/18:1(11Z))	0
PC(P-18:1(9Z)/18:1(9Z))	0
PC(P-18:1(9Z)/18:2(9Z,12Z))	0
PC(P-18:1(9Z)/18:3(6Z,9Z,12Z))	0
PC(P-18:1(9Z)/18:3(9Z,12Z,15Z))	0
PC(P-18:1(9Z)/18:4(6Z,9Z,12Z,15Z))	0
PC(P-18:1(9Z)/20:2(11Z,14Z))	0
PC(P-18:1(9Z)/20:3(5Z,8Z,11Z))	0
PC(P-18:1(9Z)/20:3(8Z,11Z,14Z))	0
PC(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z))	0
PC(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))	0
PC(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))	0
PC(P-18:1(9Z)/22:2(13Z,16Z))	0
PC(P-18:1(9Z)/24:0)	0
PC(P-18:1(9Z)/24:1(15Z))	0
PC(P-18:1(9Z)/P-16:0)	0
PC(P-18:1(9Z)/P-18:1(11Z))	0
PC(P-18:1(9Z)/P-18:1(9Z))	0
PC(P-19:1(12Z)/0:0)	0
PC(P-20:0/0:0)	0
PC(dm18:1(11Z)/20:4(8Z,11Z,14Z,17Z))	0
PC(o-16:0/20:4(8Z,11Z,14Z,17Z))	0
PC(o-16:1(9Z)/18:0)	0
PC(o-16:1(9Z)/20:0)	0
PC(o-16:1(9Z)/22:0)	0
PC(o-18:0/18:2(9Z,12Z))	0
PC(o-18:1(11Z)/16:0)	0
PC(o-18:1(11Z)/18:2(9Z,12Z))	0
PC(o-18:1(9Z)/18:0)	0
PC(o-18:1(9Z)/18:1(11Z))	0
PC(o-18:1(9Z)/18:2(9Z,12Z))	0
PC(o-18:1(9Z)/20:1(11Z))	0
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z))	0
PC(o-18:2(9Z,12Z)/20:0)	0
PC(o-18:2(9Z,12Z)/22:0)	0
PC(o-18:2(9Z,12Z)/24:0)	0
PC(o-20:0/18:3(6Z,9Z,12Z))	0
PC(o-20:0/18:3(9Z,12Z,15Z))	0
PC(o-20:1(11Z)/20:4(8Z,11Z,14Z,17Z))	0
PC(o-22:0/18:3(6Z,9Z,12Z))	0
PC(o-22:0/18:3(9Z,12Z,15Z))	0
PC(o-22:1(13Z)/22:2(13Z,16Z))	0
PC(o-22:1(13Z)/22:3(10Z,13Z,16Z))	0
PC(o-22:2(13Z,16Z)/22:2(13Z,16Z))	0
alkyl,acyl-sn-glycero-3-phosphocholine +	33
alkylacylglycero-3-phosphocholine +	33
glycerylphosphorylcholine	2
lysophosphatidylcholine +	34
monoalk-1-enyl-sn-glycero-phosphocholine	0
monoalkyl-sn-glycero-3-phosphocholine +	0
monoalkylglycerophosphocholine +	0
oxidized 1-acyl-sn-glycero-3-phosphocholine zwitterion +	0
oxidized glycerophosphocholine zwitterion +	0
phosphatidylcholine +	82
Path 2
Term	Annotations
CHEBI ontology	19867
subatomic particle	19865
composite particle	19865
hadron	19865
baryon	19865
nucleon	19865
atomic nucleus	19865
atom	19865
main group element atom	19803
p-block element atom	19803
chalcogen	19555
oxygen atom	19527
oxygen molecular entity	19527
hydroxides	19336
oxoacid	18783
pnictogen oxoacid	14974
phosphorus oxoacid	14574
phosphoric acids	13924
phosphoric acid	13924
phosphoric acid derivative	13834
phosphate	13833
organic phosphate	13833
phospholipid	322
glycerophospholipid	218
glycerophosphocholine	124
(3-hexadecoxy-2-hydroxy-2-methylpropyl) 2-(trimethylazaniumyl)ethyl phosphate	0
1,2-diacyl-sn-glycero-3-phosphocholine +	23
1,2-dialkyl-sn-glycero-3-phosphocholine +	0
1-(alk-1-enyl)-2-acyl-glycero-3-phosphocholine +	0
1-(alk-1-enyl)glycero-3-phosphocholine +	0
1-o-hexadecyl-2-o-ethyl-sn-glycero-3-phosphocholine	0
1-octadecyl-2-(1E-ethenyl)-sn-glycero-3-phosphocholine	0
1-octadecyl-2-methylglycero-3-phosphocholine +	6
1-tetradecanyl-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholine	0
1-thio-sn-glycero-3-phosphocholine +	0
2-O-ethyl PAF C-16	0
2-methyl-3-tetradecyl-sn-glycero-1-phosphocholine	0
Glycero-3-phosphocholine	0
PC(14:0/P-18:0)	0
PC(14:0/P-18:1(11Z))	0
PC(14:0/P-18:1(9Z))	0
PC(14:1(9Z)/P-18:0)	0
PC(16:0/P-16:0)	0
PC(16:0/P-18:1(11Z))	0
PC(16:0/P-18:1(9Z))	0
PC(16:1(9Z)/P-16:0)	0
PC(16:1(9Z)/P-18:0)	0
PC(16:1(9Z)/P-18:1(11Z))	0
PC(16:1(9Z)/P-18:1(9Z))	0
PC(18:0/P-18:1(11Z))	0
PC(18:0/P-18:1(9Z))	0
PC(18:1(11Z)/P-16:0)	0
PC(18:1(11Z)/P-18:0)	0
PC(18:1(11Z)/P-18:1(11Z))	0
PC(18:1(11Z)/P-18:1(9Z))	0
PC(18:1(9Z)/P-16:0)	0
PC(18:1(9Z)/P-18:0)	0
PC(18:1(9Z)/P-18:1(11Z))	0
PC(18:1(9Z)/P-18:1(9Z))	0
PC(18:2(9Z,12Z)/P-16:0)	0
PC(18:2(9Z,12Z)/P-18:0)	0
PC(18:2(9Z,12Z)/P-18:1(11Z))	0
PC(18:2(9Z,12Z)/P-18:1(9Z))	0
PC(18:3(6Z,9Z,12Z)/P-16:0)	0
PC(18:3(6Z,9Z,12Z)/P-18:0)	0
PC(18:3(6Z,9Z,12Z)/P-18:1(11Z))	0
PC(18:3(6Z,9Z,12Z)/P-18:1(9Z))	0
PC(18:3(9Z,12Z,15Z)/P-16:0)	0
PC(18:3(9Z,12Z,15Z)/P-18:0)	0
PC(18:3(9Z,12Z,15Z)/P-18:1(11Z))	0
PC(18:3(9Z,12Z,15Z)/P-18:1(9Z))	0
PC(18:4(6Z,9Z,12Z,15Z)/P-16:0)	0
PC(18:4(6Z,9Z,12Z,15Z)/P-18:1(11Z))	0
PC(18:4(6Z,9Z,12Z,15Z)/P-18:1(9Z))	0
PC(18:4(6Z,9Z,12Z,15Z)/dm18:0)	0
PC(20:1(11Z)/P-16:0)	0
PC(20:2(11Z,14Z)/P-16:0)	0
PC(20:2(11Z,14Z)/P-18:1(11Z))	0
PC(20:2(11Z,14Z)/P-18:1(9Z))	0
PC(20:3(5Z,8Z,11Z)/P-16:0)	0
PC(20:3(5Z,8Z,11Z)/P-18:0)	0
PC(20:3(5Z,8Z,11Z)/P-18:1(11Z))	0
PC(20:3(5Z,8Z,11Z)/P-18:1(9Z))	0
PC(20:3(8Z,11Z,14Z)/P-16:0)	0
PC(20:3(8Z,11Z,14Z)/P-18:0)	0
PC(20:3(8Z,11Z,14Z)/P-18:1(11Z))	0
PC(20:3(8Z,11Z,14Z)/P-18:1(9Z))	0
PC(20:4(5Z,8Z,11Z,14Z)/P-16:0)	0
PC(20:4(5Z,8Z,11Z,14Z)/P-18:0)	0
PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(11Z))	0
PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z))	0
PC(20:4(8Z,11Z,14Z,17Z)/P-16:0)	0
PC(20:4(8Z,11Z,14Z,17Z)/P-18:0)	0
PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(11Z))	0
PC(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z))	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-16:0)	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:0)	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(11Z))	0
PC(20:5(5Z,8Z,11Z,14Z,17Z)/P-18:1(9Z))	0
PC(22:2(13Z,16Z)/P-18:1(11Z))	0
PC(22:2(13Z,16Z)/P-18:1(9Z))	0
PC(22:4(7Z,10Z,13Z,16Z)/P-16:0)	0
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0)	0
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0)	0
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0)	0
PC(24:0/P-18:1(11Z))	0
PC(24:0/P-18:1(9Z))	0
PC(24:1(15Z)/P-18:0)	0
PC(24:1(15Z)/P-18:1(11Z))	0
PC(24:1(15Z)/P-18:1(9Z))	0
PC(O-10:0/O-10:0)	0
PC(O-10:0/O-12:0)	0
PC(O-12:0/O-1:0)	0
PC(O-14:0/O-1:0)	0
PC(O-16:0/O-1:0)	0
PC(O-16:1(1E)/0:0)	0
PC(O-18:1(1E)/0:0)	0
PC(O-18:1(9Z)/O-1:0)	0
PC(O-1:0/2:0)	0
PC(O-1:0/O-18:0)	0
PC(O-22:2(13Z,16Z)/22:3(10Z,13Z,16Z))	0
PC(O-24:0/18:3(9Z,12Z,15Z))	0
PC(P-14:0/0:0)	0
PC(P-16:0/18:1(11Z))	0
PC(P-16:0/18:3(6Z,9Z,12Z))	0
PC(P-16:0/18:3(9Z,12Z,15Z))	0
PC(P-16:0/18:4(6Z,9Z,12Z,15Z))	0
PC(P-16:0/20:1(11Z))	0
PC(P-16:0/20:2(11Z,14Z))	0
PC(P-16:0/20:3(5Z,8Z,11Z))	0
PC(P-16:0/20:3(8Z,11Z,14Z))	0
PC(P-16:0/20:4(8Z,11Z,14Z,17Z))	0
PC(P-16:0/22:4(7Z,10Z,13Z,16Z))	0
PC(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z))	0
PC(P-16:0/P-16:0)	0
PC(P-16:0/P-18:1(11Z))	0
PC(P-16:0/P-18:1(9Z))	0
PC(P-18:0/14:0)	0
PC(P-18:0/14:1(9Z))	0
PC(P-18:0/16:1(9Z))	0
PC(P-18:0/18:1(11Z))	0
PC(P-18:0/18:3(6Z,9Z,12Z))	0
PC(P-18:0/18:3(9Z,12Z,15Z))	0
PC(P-18:0/18:4(6Z,9Z,12Z,15Z))	0
PC(P-18:0/20:3(5Z,8Z,11Z))	0
PC(P-18:0/20:3(8Z,11Z,14Z))	0
PC(P-18:0/20:4(8Z,11Z,14Z,17Z))	0
PC(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z))	0
PC(P-18:0/24:1(15Z))	0
PC(P-18:1(11Z)/14:0)	0
PC(P-18:1(11Z)/16:0)	0
PC(P-18:1(11Z)/16:1(9Z))	0
PC(P-18:1(11Z)/18:0)	0
PC(P-18:1(11Z)/18:1(11Z))	0
PC(P-18:1(11Z)/18:1(9Z))	0
PC(P-18:1(11Z)/18:2(9Z,12Z))	0
PC(P-18:1(11Z)/18:3(6Z,9Z,12Z))	0
PC(P-18:1(11Z)/18:3(9Z,12Z,15Z))	0
PC(P-18:1(11Z)/18:4(6Z,9Z,12Z,15Z))	0
PC(P-18:1(11Z)/20:2(11Z,14Z))	0
PC(P-18:1(11Z)/20:3(5Z,8Z,11Z))	0
PC(P-18:1(11Z)/20:3(8Z,11Z,14Z))	0
PC(P-18:1(11Z)/20:4(5Z,8Z,11Z,14Z))	0
PC(P-18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))	0
PC(P-18:1(11Z)/22:2(13Z,16Z))	0
PC(P-18:1(11Z)/24:0)	0
PC(P-18:1(11Z)/24:1(15Z))	0
PC(P-18:1(11Z)/P-16:0)	0
PC(P-18:1(11Z)/P-18:1(11Z))	0
PC(P-18:1(11Z)/P-18:1(9Z))	0
PC(P-18:1(9Z)/14:0)	0
PC(P-18:1(9Z)/16:0)	0
PC(P-18:1(9Z)/16:1(9Z))	0
PC(P-18:1(9Z)/18:0)	0
PC(P-18:1(9Z)/18:1(11Z))	0
PC(P-18:1(9Z)/18:1(9Z))	0
PC(P-18:1(9Z)/18:2(9Z,12Z))	0
PC(P-18:1(9Z)/18:3(6Z,9Z,12Z))	0
PC(P-18:1(9Z)/18:3(9Z,12Z,15Z))	0
PC(P-18:1(9Z)/18:4(6Z,9Z,12Z,15Z))	0
PC(P-18:1(9Z)/20:2(11Z,14Z))	0
PC(P-18:1(9Z)/20:3(5Z,8Z,11Z))	0
PC(P-18:1(9Z)/20:3(8Z,11Z,14Z))	0
PC(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z))	0
PC(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z))	0
PC(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))	0
PC(P-18:1(9Z)/22:2(13Z,16Z))	0
PC(P-18:1(9Z)/24:0)	0
PC(P-18:1(9Z)/24:1(15Z))	0
PC(P-18:1(9Z)/P-16:0)	0
PC(P-18:1(9Z)/P-18:1(11Z))	0
PC(P-18:1(9Z)/P-18:1(9Z))	0
PC(P-19:1(12Z)/0:0)	0
PC(P-20:0/0:0)	0
PC(dm18:1(11Z)/20:4(8Z,11Z,14Z,17Z))	0
PC(o-16:0/20:4(8Z,11Z,14Z,17Z))	0
PC(o-16:1(9Z)/18:0)	0
PC(o-16:1(9Z)/20:0)	0
PC(o-16:1(9Z)/22:0)	0
PC(o-18:0/18:2(9Z,12Z))	0
PC(o-18:1(11Z)/16:0)	0
PC(o-18:1(11Z)/18:2(9Z,12Z))	0
PC(o-18:1(9Z)/18:0)	0
PC(o-18:1(9Z)/18:1(11Z))	0
PC(o-18:1(9Z)/18:2(9Z,12Z))	0
PC(o-18:1(9Z)/20:1(11Z))	0
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z))	0
PC(o-18:2(9Z,12Z)/20:0)	0
PC(o-18:2(9Z,12Z)/22:0)	0
PC(o-18:2(9Z,12Z)/24:0)	0
PC(o-20:0/18:3(6Z,9Z,12Z))	0
PC(o-20:0/18:3(9Z,12Z,15Z))	0
PC(o-20:1(11Z)/20:4(8Z,11Z,14Z,17Z))	0
PC(o-22:0/18:3(6Z,9Z,12Z))	0
PC(o-22:0/18:3(9Z,12Z,15Z))	0
PC(o-22:1(13Z)/22:2(13Z,16Z))	0
PC(o-22:1(13Z)/22:3(10Z,13Z,16Z))	0
PC(o-22:2(13Z,16Z)/22:2(13Z,16Z))	0
alkyl,acyl-sn-glycero-3-phosphocholine +	33
alkylacylglycero-3-phosphocholine +	33
glycerylphosphorylcholine	2
lysophosphatidylcholine +	34
monoalk-1-enyl-sn-glycero-phosphocholine	0
monoalkyl-sn-glycero-3-phosphocholine +	0
monoalkylglycerophosphocholine +	0
oxidized 1-acyl-sn-glycero-3-phosphocholine zwitterion +	0
oxidized glycerophosphocholine zwitterion +	0
phosphatidylcholine +	82

paths to the root